Target Price | €43.96 |
Price | €41.12 |
Potential | 6.92% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €43.96. This is 6.92% higher than the current stock price. The highest price target is €49.58 20.59% , the lowest is €39.02 5.10% . | |
A rating was issued by 24 analysts: 14 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 6.92% . Most analysts recommend the Qiagen stock at Purchase. |
27 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 3.18% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 7.86% , the lowest is €1.7b 2.46% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 6.41% |
2026 | €1.9b | 5.70% |
2027 | €2.0b | 6.97% |
2028 | €2.3b | 12.52% |
2029 | €2.5b | 9.82% |
2030 | €2.9b | 14.08% |
24 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €676m . This is 44.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €759m 61.38% , the lowest is €592m 25.84% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €434m | 10.64% |
---|---|---|
2025 | €676m | 56.08% |
2026 | €733m | 8.47% |
2027 | €793m | 8.11% |
2028 | €855m | 7.85% |
2029 | €914m | 6.83% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.41% | 46.67% |
2026 | 38.39% | 2.62% |
2027 | 38.80% | 1.07% |
2028 | 37.19% | 4.15% |
2029 | 36.18% | 2.72% |
27 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €446m . This is 39.09% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €464m 44.32% , the lowest is €425m 32.26% .
This results in the following potential growth metrics and future Net Margins:
2024 | €72.0m | 75.51% |
---|---|---|
2025 | €446m | 521.32% |
2026 | €484m | 8.61% |
2027 | €531m | 9.69% |
2028 | €596m | 12.17% |
2029 | €635m | 6.55% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.67% | 483.83% |
2026 | 25.35% | 2.76% |
2027 | 26.00% | 2.56% |
2028 | 25.92% | 0.31% |
2029 | 25.14% | 3.01% |
27 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.06 . This is 41.10% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.14 46.58% , the lowest is €1.96 34.25% .
This results in the following potential growth metrics and future valuations:
2024 | €0.33 | 75.00% |
---|---|---|
2025 | €2.06 | 524.24% |
2026 | €2.23 | 8.25% |
2027 | €2.45 | 9.87% |
2028 | €2.75 | 12.24% |
2029 | €2.93 | 6.55% |
Current | 28.16 | 80.92% |
---|---|---|
2025 | 19.97 | 29.02% |
2026 | 18.39 | 7.91% |
2027 | 16.77 | 8.81% |
2028 | 14.95 | 10.85% |
2029 | 14.03 | 6.15% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 5.18 and an P/S ratio of 4.94 .
This results in the following potential growth metrics and future valuations:
Current | 5.34 | 6.64% |
---|---|---|
2025 | 5.18 | 3.09% |
2026 | 4.90 | 5.39% |
2027 | 4.58 | 6.51% |
2028 | 4.07 | 11.13% |
2029 | 3.70 | 8.94% |
2030 | 3.25 | 12.34% |
Current | 5.10 | 6.59% |
---|---|---|
2025 | 4.94 | 3.08% |
2026 | 4.68 | 5.39% |
2027 | 4.37 | 6.51% |
2028 | 3.88 | 11.13% |
2029 | 3.54 | 8.94% |
2030 | 3.10 | 12.34% |
Analyst | Rating | Action | Date |
---|---|---|---|
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Analyst Rating | Date |
---|---|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.